<DOC>
	<DOCNO>NCT01901640</DOCNO>
	<brief_summary>Phase : Phase III Indication : Erectile Dysfunction Study Design : open-label , fix dose , 6-month extension study ( parent study : DA8159_EDD_III )</brief_summary>
	<brief_title>Safety Study Once-a-Day Dosing Udenafil Treat Erectile Dysfunction</brief_title>
	<detailed_description>Completer parent study ( DA8159_EDD_III ) continue 24weeks open-label extension receive udenafil daily . The study conclude 4-week ED treatment-free period .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Udenafil</mesh_term>
	<criteria>Male patient age 20 year diagnose erectile dysfunction ( ED ) Had uncontrolled blood pressure Had hepatic renal dysfunction Had significant psychiatric disorder drug abuse Was currently anticancer chemotherapy Had treatment ED use phosphodiesterase type 5 ( PDE5 ) inhibitor</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>